Zum Inhalt springen
Nachrichten

Duodenal Mucosal Resurfacing Reduces Weight Regain After Stopping GLP-1 Drugs Duodenal Mucosal Resurfacing Reduces Weight Regain After GLP-1 Therapy

Research presented at Digestive Disease Week 2026 shows a minimally invasive procedure called duodenal mucosal resurfacing may prevent weight regain after stopping GLP-1 medications like Ozempic or Wegovy.

About 70% of patients regain weight within 18 months of stopping GLP-1 drugs

Nearly one in five adults with obesity has used a glucagon-like peptide-1 agonist, highlighting the widespread challenge of sustaining weight loss after discontinuation. In the study, all participants had previously lost at least 15% of their body weight using tirzepatide before stopping the drug. On average, patients lost about 40 pounds even as on GLP-1 therapy.

Duodenal mucosal resurfacing uses heat to renew intestinal lining

The procedure removes damaged tissue from the duodenum’s inner lining using controlled heat, encouraging growth of healthier tissue. Researchers theorize this renewal triggers a lasting metabolic reset that helps maintain weight loss without ongoing medication. The ongoing REMAIN-1 trial is testing whether this approach sustains benefits after stopping drugs like semaglutide or tirzepatide.

Trial results show treated group regained significantly less weight

Among 45 participants with six months of follow-up, 29 received the resurfacing treatment while 16 underwent a sham procedure. Those who had the actual treatment regained less weight, with more extensive resurfacing linked to only about 7 pounds regained and over 80% of initial loss maintained. The control group regained roughly twice as much weight as the treatment group. Participants in the sham group regained about 40% more weight than those who received the real procedure.

Trial results show treated group regained significantly less weight
Duodenal Mucosal Resurfacing Reduces Weight Regain After Stopping Drugs Duodenal Mucosal Resurfacing Reduces Weight Regain After Digestive Disease Week

Is duodenal mucosal resurfacing currently available to patients?

No, the procedure remains investigational and is only being studied in the ongoing REMAIN-1 trial; it is not yet approved for general use.

How long do the effects of the procedure last?

The study only includes six months of follow-up data; longer-term durability is still under investigation and not yet known.

Duodenal Mucosal Resurfacing with Revita DMR
Teilen Facebook X WhatsApp E-Mail
Johann Falk

Über den Autor

Johann Falk ist Chief Editor von Germanic Nachrichten und verantwortet die redaktionelle Linie, Themenauswahl und finale Qualitaetssicherung der Veroeffentlichung. Sein Schwerpunkt liegt auf klarer, verifizierter und schnell einordenbarer Berichterstattung fuer ein deutschsprachiges Publikum.

Alle Beiträge erscheinen nach redaktioneller Prüfung gemäß unseren Redaktionsrichtlinien.

Schreibe einen Kommentar

Diese Website verwendet Akismet, um Spam zu reduzieren. Erfahre, wie deine Kommentardaten verarbeitet werden.